MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 106 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,899,783 | -4.9% | 5,204,942 | +28.3% | 2.26% | -3.9% |
| Q2 2023 | $44,065,655 | +32.2% | 4,057,611 | -16.0% | 2.36% | +67.3% |
| Q1 2023 | $33,335,701 | +73.7% | 4,831,261 | +0.2% | 1.41% | +74.7% |
| Q4 2022 | $19,195,520 | -18.4% | 4,822,995 | +36.3% | 0.81% | -17.5% |
| Q3 2022 | $23,526,000 | +38.5% | 3,537,700 | +0.8% | 0.98% | +51.2% |
| Q2 2022 | $16,992,000 | -34.3% | 3,510,831 | +26.9% | 0.65% | -18.2% |
| Q1 2022 | $25,862,000 | -17.5% | 2,766,000 | +4.8% | 0.79% | +30.1% |
| Q4 2021 | $31,349,000 | +25.4% | 2,638,775 | +20.1% | 0.61% | +44.2% |
| Q3 2021 | $25,007,000 | -23.7% | 2,197,426 | +20.3% | 0.42% | -14.1% |
| Q2 2021 | $32,766,000 | +15.9% | 1,826,445 | 0.0% | 0.49% | +17.2% |
| Q1 2021 | $28,273,000 | +62.0% | 1,826,445 | +27.7% | 0.42% | +67.9% |
| Q4 2020 | $17,448,000 | +74.1% | 1,430,172 | +83.4% | 0.25% | +38.3% |
| Q3 2020 | $10,019,000 | – | 779,725 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |